Evaluation of prophylactic granulocyte colony-stimulating factor before chemotherapy on children's with malignant neuroblastoma

Comparison of the effect of prophylactic granulocyte colony-stimulating factor versus placebo on neutrophil count before chemotherapy on children with malignant neuroblastoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050717610N1

Enrollment

Registered

2014-09-27

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant noroblastoma. Adrenal gland, unspecified

Interventions

Intervention 1: Intervention group: granulocyte colony stimulating factor three times prior to chemotherapy and one time after the chemotherapy. Intervention 2: Control group: placebo, three times pri

Treatment - Drugs

Intervention group: granulocyte colony stimulating factor three times prior to chemotherapy and one time after the chemotherapy

Control group: placebo, three times prior to chemotherapy and one time after the chemotherapy

Eligibility

Sex/Gender

All

Age

6 Months to 15 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: pathologically confirmed neuroblastoma; age below 16 years; stage 3 and 4 of disease; normal cell counts before each cycle of chemotherapy; absolute neutrophil count above 1000 and platelet count above 100000 per cubic microliter Exclusion Criteria: previous history of receiving granulocyte colony stimulating factor

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Increased numbers of neutrophils. Timepoint: 3 days. Method of measurement: Complete blood count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mir Hamid Rabbani Shabestary

Tabriz Children's hospital

rabbanihamid@yahoo.com+98 41 3526 2277

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026